Neoadjuvant Immunotherapy in Advanced NSCLC

Status Not yet recruiting

Clinical Trial Summary

A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. One such example would be to evaluate either single agent or an immunotherapy combination with chemotherapy. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.

Clinical Trial Description

A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. [The Power Life Sciences Investigative Team](https://www.withpower.com) is running a study to evaluate either single agent or an immunotherapy combination with chemotherapy. Patients can contact a site administrator via the information below, or enroll directly via <a href="https://www.withpower.com/trial/phase-4-2019-e67c1">https://www.withpower.com/trial/pha se-4-2019-e67c1</a>. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05137912
Study type	Observational
Source	Power Life Sciences Inc.
Contact	Michael B Gill
Phone	(415) 900-4227
Email	bask@withpower.com
Status	Not yet recruiting
Phase
Start date	February 1, 2022
Completion date	December 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05598528` - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Completed	`NCT03836469` - Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
Completed	`NCT01772225` - NSCLC Burden of Illness Study	N/A
Completed	`NCT01362296` - An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT01460472` - Immunotherapy With Racotumomab in Advanced Lung Cancer	Phase 3
Recruiting	`NCT03803137` - Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection	N/A
Completed	`NCT00528281` - A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase	Phase 1
Not yet recruiting	`NCT04592666` - Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer	Phase 2
Terminated	`NCT00480025` - GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT05784142` - Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)	Phase 2
Active, not recruiting	`NCT04475939` - Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer	Phase 3
Withdrawn	`NCT01938456` - Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer	Phase 1
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Recruiting	`NCT05565378` - A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04986670` - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer	N/A
Completed	`NCT00367679` - Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT00073008` - A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04581824` - Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Phase 2
Completed	`NCT00619424` - A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04940936` - Shared Decision Making on Radiation Dose for Lung Malignancies	N/A